Recent Finacing
Recent Raise
Pharvaris is a clinical-stage biopharma developing oral bradykinin B2-receptor antagonists, including PHVS416 for on-demand and extended-release prophylactic treatment of hereditary angioedema.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Pharvaris.
